Log in
Donate

Clinical Trial: SWOG S1418

SWOG S1418

Status: Closed

NCT#02954874

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy

S1418 Step 1 Registration is permanently closed to accrual effective June 30, 2021, at 12:oo pm Pacific Time.

S1418 Step 2 Registration is permanently closed to accrual effective August 21, 2021, at 11:59 pm Pacific Time.

Effective June 23, 2020, the BAHO substudy for SWOG study S1418/BR006,  is permanently closed to accrual.

View All Clinical Trials
The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved